November 14, 2025

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Classification of US FDA Inspection at Unit-I of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company as Voluntary Action Indicated (VAI) – Reg.,

Ref: Our earlier letters dated January 14, 2022 and August 29, 2025

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that –

In continuation to the warning letter issued in January 2022, the United States Food and Drug Administration (US FDA) had conducted a for cause inspection at Unit-I from August 21 to August 29, 2025. After completion of this inspection, the US FDA had issued Form 483 with 5 observations.

Unit I is an API manufacturing facility of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at Borpatla Village, Hatnoor Mandal, Sangareddy District, 502296, Telangana.

The US FDA has now completed its evaluation of the corrective actions submitted in response to Warning Letter dated January 14, 2022 including subsequent 5 observations from Form 483 and has determined that the issues cited in the Warning Letter & Form 483 have been adequately addressed. Accordingly, the Warning Letter is considered closed. The Unit has now received Establishment Inspection Report (EIR) classifying the facility as **"Voluntary Action Indicated" ("VAI")**. FDA has concluded that this inspection is closed.

The details of action initiated by US FDA in the prescribed format as required under Regulation 30 of the SEBI Listing Regulations are enclosed herewith as Annexure

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by ADI REDDY BADDIGAM
Date: 2025.11.14 10:25:16 +05'30'

B. Adi Reddy
Company Secretary

Encl.: Annexure

Annexure

S.No	Particulars	Details
1.	Name of the authority	US Food and Drug Administration (US FDA), USA
2.	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	The United States Food and Drug Administration (US FDA) had conducted a for cause inspection at Unit-I, from August 21 to August 29, 2025. After completion of this inspection the US FDA had issued Form 483 with 5 observations. Unit I is an API manufacturing facility, of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at Borpatla Village, Hatnoor Mandal, Sangareddy District, 502296, Telangana. The U.S. FDA has now completed its evaluation of the corrective actions submitted in response to Warning Letter dated January 14, 2022 including subsequent 5 observations from Form 483 and has determined that the issues cited in the Warning Letter & Form 483 have been adequately addressed. Accordingly, the Warning Letter is considered closed. The Unit has now received Establishment Inspection Report (EIR) classifying the facility as **"Voluntary Action Indicated" ("VAI")**. FDA has concluded that this inspection is closed.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	November 13, 2025
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	The Unit has now received Establishment Inspection Report (EIR) classifying the facility as "Voluntary Action Indicated" ("VAI"). FDA has concluded that this inspection is closed.
5.	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	Since the Unit has received EIR with VAI, this will have positive impact on the operations of the Unit.

Digitally signed by ADI REDDY BADDIGAM
Date: 2025.11.14 10:25:39 +05'30'